Click here to see the meta data of this asset.

Pharmacotherapy for alcohol dependence

Table 6.2 Pharmacotherapy for alcohol dependence*

 

 
 

Medication features

Contra- indications

Dose

Monitoring

Duration of therapy

Naltrexone (Revia)

Opioid receptor antagonist

 

Decreases crav- ing for alcohol and minimizes relapse if it oc- curs

Acute hepa- titis or liver failure, cau- tion in cirrhosis

 

Opoid dependence

25 mg × 3d

 

then 50 mg qd

 

may increase

to max 150 mg qd

At high doses can cause reversible elevations in transaminases

 

Frequency of monitoring is determined

by baseline levels**

3 – 6 months***

Acamprosate (Campral)

Glutamate recep- tor modulator

 

Reduces symp- toms of post- acute withdrawal (e.g., insomnia, anxiety and rest- lessness)

Severe renal impairment

666 mg tid

No labora-

tory monitoring needed

 

Monitor for di- arrhea (a com- mon adverse effect)

Up to

1 year

 

Re-evaluate q3m

Disulfiram (Antabuse)

If alcohol is con- sumed, causes toxic build-up

of acetaldehyde by binding to acetaldehyde dehydrogenase

 

Potentially fatal reaction

Unstable angina, recent MI

 

Schizophrenia and other psy- chotic illness

 

Pregnancy

 

Severe cir- rhosis

 

Precautions with many diseases

125 – 250 mg hs

Transaminases at baseline,

2 weeks then monthly × 3m

3 – 6 months***

*Combination therapy no more effective than monotherapy.

** If < 1.5 × normal repeat monthly × three months, less frequently thereafter; if 1.5 – 3 × normal repeat in two weeks; if > 3 × normal or elevated bilirubin withhold medication and repeat in two weeks.

 

*** Treatment can be continued after six months if no adverse effects.